読み込み中
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
前日終値
$3.94
+$0.20 · +5.35%
日中の時刻はETです。市場データは遅延する場合があります。
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
日中レンジ
現在 $3.94
52週レンジ
現在 $3.94
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
39
割高
センチメント
76
強気
リスク
63
高リスク
モメンタム
41
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
日中レンジ
現在 $3.94
52週レンジ
現在 $3.94
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | — | 31.7万 USD | 208万 USD |
| 売上原価 | 69.89万 USD | — | — | 15.81万 USD | 115.31万 USD |
| 粗利益 | −69.89万 USD | — | — | 15.88万 USD | 92.69万 USD |
| 研究開発 | 4204.85万 USD | 4796.44万 USD | 4162.4万 USD | 3626.71万 USD | 2654.1万 USD |
| 販売・一般管理 | 1729.82万 USD | 1607.8万 USD | 1676万 USD | 1560.7万 USD | 827.2万 USD |
| 営業費用 | 5867.71万 USD | 6407.14万 USD | 5841.29万 USD | 5190.37万 USD | 3481.3万 USD |
| 受取利息 | 303.94万 USD | 259.33万 USD | 360.7万 USD | 101.45万 USD | 16.99万 USD |
| 減価償却費と償却費 | 35.38万 USD | 38.51万 USD | 35.21万 USD | 27.73万 USD | 15.91万 USD |
| 営業利益 | −5937.6万 USD | −6407.14万 USD | −5841.29万 USD | −5174.49万 USD | −3388.61万 USD |
| 純利益 | −5602.49万 USD | −6103.66万 USD | −5347.16万 USD | −5051.36万 USD | −3353.57万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$15.50
上昇余地（293.40%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI810.16万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM541.03万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF315.23万0.00%954億 USD0.05%$235+0.80%
iShares Biotechnology ETFIBB166.84万0.02%108.2億 USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO153.36万0.01%180億 USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC66.22万0.05%13.17億 USD0.60%$183+0.11%
ALPS Medical Breakthroughs ETFSBIO32.14万0.17%1.91億 USD0.50%$55.04+2.03%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM29万0.25%1.17億 USD0.73%$15.9402+0.25%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCALPS Medical Breakthroughs ETFSBIOEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
